Navigation Links
Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
Date:5/30/2012

SAN FRANCISCO, May 30, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the Jefferies 2012 Global Healthcare Conference at The Grand Hyatt New York on Tuesday, June 5, 2012 at 11:30 a.m. Eastern Time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until July 5, 2012.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic in development to treat chronic pain, has completed Phase 1 development and is being prepared for a Phase 2 study.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharm
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... YORK , May 22, 2013 While ... their teens, friends to drink at home under adult ... about drinking, the truth is that there are serious ... Partnership at Drugfree.org and The Treatment Research ... new, interactive web resource for parents and caregivers to ...
(Date:5/22/2013)... 2013 PRNewswire – iBio, Inc. (NYSE ... vaccine candidate for the newly emerged H7N9 influenza ... the iBioLaunch™ platform. This validation milestone was achieved ... sequence information to purification of recombinant protein. ... The iBioLaunch platform eliminates the need to ...
(Date:5/22/2013)... 22, 2013 WomanCare Global recently launched ... an extensive training initiative attended by 90 health ... ) (Logo: http://photos.prnewswire.com/prnh/20101018/DC83896LOGO ) Simplant, ... highly effective subdermal implant composed of two thin, ... (a synthetic form of the hormone progestin). These ...
Breaking Medicine Technology:Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 2Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 3Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 4Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 5Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 6Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 7iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza 2WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile 2
... SAN DIEGO, Feb. 3, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... report its fourth quarter and year-end 2010 financial results after ... will then host a live conference call and webcast to ... afternoon, February 10, 2011 at 5:00 p.m. Eastern Time (2:00 ...
... 2011 SkinMedica, Inc., the fastest-growing professional skin ... that it is introducing a new, fast-acting anti-redness ... in over two decades.  It is the first ... visible redness.     (Photo: ...
Cached Medicine Technology:SkinMedica Launches Redness Relief CalmPlex™ 2SkinMedica Launches Redness Relief CalmPlex™ 3
(Date:5/22/2013)... , , TUESDAY, May 21 (HealthDay News) -- The overall ... in 10 people either overweight or obese and large ... or not exercising, a new government report shows. , ... Control and Prevention, the report found Americans continuing to ... to soaring rates of heart disease, diabetes and other ...
(Date:5/22/2013)... Teams who focus on productivity, process, quality, ... Do-Done StepTracker whiteboard as a rallying point for project ... display the current status of our company-wide lean initiatives ... is listed down the side and the milestones are ... squares are filled with yellow circles. Turning the magnets ...
(Date:5/22/2013)... Paris, France: Results from a large observational ... whether bivalirudin is superior to heparin in ... 30-day mortality in patients with non-ST segment ... coronary intervention (PCI)., European and US NSTE-ACS ... alternative to unfractionated heparin plus GP IIb/IIIa ...
(Date:5/22/2013)... 22, 2013 The PreDiabetes Center ... in the Greater Philadelphia Tour de Cure, a premier cycling ... are passionate about stopping the spread of diabetes , ... , The Tour de Cure will take place Saturday, ... Road in Ambler, 30 minutes outside of Philadelphia, between the ...
(Date:5/22/2013)... New York City, New York (PRWEB) May 22, 2013 ... Black American: Causes, Culture, Consequences, and Cost ” article published ... on obesity is fully justified. The Centers for Disease ... of U.S. adults aged 20 and over are overweight, 35.7% ... alarming facts are highlighted in this investigative article. In particular, ...
Breaking Medicine News(10 mins):Health News:Americans Still Making Unhealthy Choices: CDC 2Health News:Americans Still Making Unhealthy Choices: CDC 3Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2Health News:Registry questions superiority of bivalirudin over heparin 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 2Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 3
... Dr. Eric Olson, chairman of molecular biology at UT ... France,s prestigious Lefoulon-Delalande Foundation Grand Prize for his work ... The prize has an international reputation as the ... about $664,000 (500,000 euros) will be presented June 10 ...
... , LOUISVILLE, Colo., June 4 /PRNewswire/ -- ... 13 GHXcellence Awards for achievements in improving supply chain performance. ... a recognition ceremony in Nashville at the 9th Annual GHX ... focused on both the buy and sell side of the ...
... The Minneapolis-St. Paul office of Weber Shandwick has been ... the organization,s largest annual awareness campaign. The "Be The ... to reach a diverse audience of current and potential ... with leukemia and other life-threatening diseases, a marrow transplant ...
... to Reduce Administrative Costs in Healthcare and Streamlines Processes ... N.J., June 4 MD On-Line Inc ... core focus of converting paper submitting providers to electronic ... Corp. (MCC) of Bristol, CT. Both are EHNAC-accredited ...
... nursing homes with one in four residents carrying the bacteria, a ... Its authors say that the findings, which have been ... highlight the need for infection control strategies to be given a ... be the largest of its kind studying MRSA in private nursing ...
... Fitness and Nutrition Program from Fitness Expert Monique Hollowell ... often feel their bodies will never be the same ... a fit pregnancy, less painful birth and quick recovery ... and personal trainer, Monique Hollowell has created a fitness ...
Cached Medicine News:Health News:UT Southwestern's Olson wins prestigious French award for heart research 2Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 2Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 3Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 2Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 3Health News:MD On-Line Inc. Acquires Medical Claim Corp. 2Health News:1 in 4 nursing home residents carry MRSA 2Health News:Keys to a Fit Pregnancy and Losing the Baby Weight 2Health News:Keys to a Fit Pregnancy and Losing the Baby Weight 3
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th...
... Medical is the world leader in ... used worldwide for permanent pacemaker and ... and port implantation, and for temporary ... St. Jude Medical Peel-Away introducers includes ...
... Stent System combines low-profile, high radial force, and ... wire compatible stent system provides 6F sheath / ... - 10.0 mm). Now, with longer stents available, ... stent lengths (28, 38, 56, 80 and 100 ...
... transseptal left heart catheterization occurs when the ... a sheath with an alternate curve while ... an exchange has required a repeat septal ... has overcome this problem with the unique ...
Medicine Products: